Consolidated Entities and Acquisitions - Entasis Therapeutics Holdings, Inc. (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Subsidiary or Equity Method Investee [Line Items]
Total purchase price	$ 453,500		$ 453,500
Net loss attributable to Innoviva stockholders	$ 36,532	$ 34,865